Literature DB >> 36216881

Endosomal trafficking in metabolic homeostasis and diseases.

Jerome Gilleron1, Anja Zeigerer2,3.   

Abstract

The global prevalences of obesity and type 2 diabetes mellitus have reached epidemic status, presenting a heavy burden on society. It is therefore essential to find novel mechanisms and targets that could be utilized in potential treatment strategies and, as such, intracellular membrane trafficking has re-emerged as a regulatory tool for controlling metabolic homeostasis. Membrane trafficking is an essential physiological process that is responsible for the sorting and distribution of signalling receptors, membrane transporters and hormones or other ligands between different intracellular compartments and the plasma membrane. Dysregulation of intracellular transport is associated with many human diseases, including cancer, neurodegeneration, immune deficiencies and metabolic diseases, such as type 2 diabetes mellitus and its associated complications. This Review focuses on the latest advances on the role of endosomal membrane trafficking in metabolic physiology and pathology in vivo, highlighting the importance of this research field in targeting metabolic diseases.
© 2022. Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36216881     DOI: 10.1038/s41574-022-00737-9

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   47.564


  218 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 2.  Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals.

Authors:  Jean Jacques Noubiap; Jobert Richie Nansseu; Eric Lontchi-Yimagou; Jan René Nkeck; Ulrich Flore Nyaga; Anderson T Ngouo; Dahlia Noelle Tounouga; Frank-Leonel Tianyi; Audrey Joyce Foka; Aude Laetitia Ndoadoumgue; Jean Joel Bigna
Journal:  Diabetes Res Clin Pract       Date:  2022-05-15       Impact factor: 5.602

3.  Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.

Authors:  Naveed Sattar; Allan Gaw; Olga Scherbakova; Ian Ford; Denis St J O'Reilly; Steven M Haffner; Chris Isles; Peter W Macfarlane; Chris J Packard; Stuart M Cobbe; James Shepherd
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

4.  Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.

Authors:  David E Laaksonen; Hanna-Maaria Lakka; Leo K Niskanen; George A Kaplan; Jukka T Salonen; Timo A Lakka
Journal:  Am J Epidemiol       Date:  2002-12-01       Impact factor: 4.897

5.  Once-Weekly Semaglutide in Adults with Overweight or Obesity.

Authors:  John P H Wilding; Rachel L Batterham; Salvatore Calanna; Melanie Davies; Luc F Van Gaal; Ildiko Lingvay; Barbara M McGowan; Julio Rosenstock; Marie T D Tran; Thomas A Wadden; Sean Wharton; Koutaro Yokote; Niels Zeuthen; Robert F Kushner
Journal:  N Engl J Med       Date:  2021-02-10       Impact factor: 91.245

6.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Authors:  Tamer Coskun; Kyle W Sloop; Corina Loghin; Jorge Alsina-Fernandez; Shweta Urva; Krister B Bokvist; Xuewei Cui; Daniel A Briere; Over Cabrera; William C Roell; Uma Kuchibhotla; Julie S Moyers; Charles T Benson; Ruth E Gimeno; David A D'Alessio; Axel Haupt
Journal:  Mol Metab       Date:  2018-10-03       Impact factor: 7.422

Review 7.  Multi-Target Approaches in Metabolic Syndrome.

Authors:  Felix F Lillich; John D Imig; Ewgenij Proschak
Journal:  Front Pharmacol       Date:  2021-03-12       Impact factor: 5.810

Review 8.  Anti-obesity drug discovery: advances and challenges.

Authors:  Timo D Müller; Matthias Blüher; Matthias H Tschöp; Richard D DiMarchi
Journal:  Nat Rev Drug Discov       Date:  2021-11-23       Impact factor: 112.288

Review 9.  Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.

Authors:  Young Jin Tak; Sang Yeoup Lee
Journal:  World J Mens Health       Date:  2020-03-09       Impact factor: 5.400

Review 10.  The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Branka Filipovic; Snezana Lukic; Dragana Mijac; Marija Marjanovic-Haljilji; Marko Vojnovic; Jelena Bogdanovic; Tijana Glisic; Natasa Filipovic; Jamal Al Kiswani; Aleksandra Djokovic; Suncica Kapor; Slobodan Kapor; Zoran Bukumiric; Ana Starcevic
Journal:  Int J Mol Sci       Date:  2021-12-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.